COVID-19: New EMCDDA study highlights drop in availability of drug services in Europe but increase in innovation

Désolé, cet article est seulement disponible en Anglais.

As Europe grapples with the unprecedented public health threat posed by COVID-19, how is the outbreak affecting drug users and service providers? In a new study published on May 12, 2020, — Impact of COVID-19 on drug services and help-seeking in Europe — the EMCDDA reports signs of a drop in the availability of drug services during the pandemic and in the numbers of those seeking help. But the study also provides insight into how services have adapted and innovated during the fast-changing crisis in ways that could be carried forward into the future.

The report is the first in a series of briefings resulting from an EMCDDA ‘trendspotter’ study, launched in April to explore the impact of COVID-19 on the drug situation and responses to it. The agency’s trendspotter methodology explores emerging drug-related trends by rapidly collecting and triangulating data from a variety of sources to allow for timely assessments of topics of concern. Due to national emergency restrictions, the method was adapted to suit online investigation and the study designed to be carried out in successive waves (1). The findings released today stem from the first wave of the investigation which focused on drug services.

Read more

EMCDDA trendspotter briefing – Impact of COVID-19 on drug services and help-seeking in Europe

Twitter Facebook LinkedIn Pinterest Email